Colosafe
Commercial- Indications
- Colorectal cancer
Company intelligence / Profile preview
Creative Biosciences
Guangzhou, Guangdong, Chinaen.creativebio.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Creative Biosciences has commercialized Colosafe®, a stool DNA-based test for early colorectal cancer screening. The company is also developing additional noninvasive molecular diagnostic kits for other cancers such as lung, bladder, cervical, and liver. These products are at various stages of development and regulatory approval; Colosafe® has received CE Mark and Chinese NMPA Class III approval[1].
- Therapeutic areas
- Oncology
- Modalities
- Diagnostic kitMolecular diagnostics (including sDNA test)
- Industry
- Molecular Diagnostics
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Creative Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Creative Biosciences.